Engineered immune cells take aim at stubborn blood cancers
NCT ID NCT07679919
First seen Jul 01, 2026 · Last updated Jul 02, 2026 · Updated 1 time
Summary
This phase 1 trial is testing a new kind of CAR-T cell therapy, called LMY-922, for people with certain blood cancers that have not responded to standard treatments. The therapy uses donor immune cells engineered to target a protein called BAFF on cancer cells. The study aims to find a safe dose and look for early signs that the treatment can shrink tumors.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- LMY-922 (BAFF CAR-T cells)
- What this could lead to
- If successful, this could offer a new treatment option for people with blood cancers that have not responded to standard therapies, including those who have relapsed after other CAR-T treatments.
- What could go wrong
- This is an early phase 1 trial with only 27 participants, so the main goal is safety, not proof of effectiveness. The therapy may cause serious side effects or fail to shrink tumors.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC LYMPHOCYTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Taussig Cancer Institute | Cleveland Clinic
Cleveland, Ohio, 44195, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could muscle loss predict blood cancer outcomes?
- Can a Triple-Action antibody deepen remissions in myeloma?
- A shot at safer CAR t: early brain protection for lymphoma patients?
- Can a Low-Dose antifungal shield vulnerable patients from deadly fungal infections?
- Can a gentler chemo prep make stem cell transplants safer for blood cancer patients?
- Engineered immune cells take aim at Hard-to-Treat lymphomas